Clinical Trials on Nasopharyngeal Melanoma

Total 4059 results

University of Turku

Completed

Bevacizumab, Dacarbazine and Interferon-Alfa to Treat Metastatic Melanoma

Metastatic Melanoma

Finland
University Hospital Tuebingen

Completed

Intradermal Vaccination With Stabilized Tumor mRNA - a Clinical Phase I/II Trial in Melanoma Patients

Malignant Melanoma

Germany
Cytos Biotechnology AG

Completed

Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients

Malignant Melanoma

Switzerland
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

Pembrolizumab in Treating Patients With Advanced Uveal Melanoma

Stage IV Uveal Melanoma | Stage IIIA Uveal Melanoma | Stage IIIB Uveal Melanoma | Stage IIIC Uveal Melanoma

United States
National Taiwan University Hospital

Unknown

Role of SLURP-1 in Melanoma and Melanoma Stem Cells

Melanoma;

Taiwan
National Cancer Institute (NCI)

Completed

VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Recurrent Melanoma | Stage IV Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage III Melanoma | Extraocular Extension Melanoma

United States
University of California, San Francisco
Merck Sharp & Dohme LLC

Completed

Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma

Stage III Cutaneous Melanoma | Stage IIIA Cutaneous Melanoma | Stage IIIB Cutaneous Melanoma | Stage IIIC Cutaneous Melanoma | Stage IV Cutaneous Melanoma

United States
Takara Bio Inc.

Completed

A Study of Combination With TBI-1401(HF10) and Ipilimumab in Japanese Patients With Unresectable or Metastatic Melanoma

Melanoma Stage IV | Melanoma Stage III

Japan
National Cancer Institute (NCI)

Active, not recruiting

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

Metastatic Melanoma | Recurrent Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Completed

Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery

Stage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma

United States
National Cancer Institute (NCI)

Completed

Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery

Stage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma

United States
Medical University of Graz
Bristol-Myers Squibb

Terminated

The IRMI-FMT Trial

Malignant Melanoma Stage III | Malignant Melanoma Stage IV | Fecal Microbiota Transplantation

Austria
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma

Malignant Solid Neoplasm | Metastatic Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States
National Cancer Institute (NCI)

Completed

Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma

Stage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIIA Skin Melanoma

United States
National Cancer Institute (NCI)

Completed

Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye

Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Extraocular Extension Melanoma

United States
Elizabeth Buchbinder, MD
Genentech, Inc.

Recruiting

A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma

Stage IV Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Unresectable Stage III Cutaneous Melanoma | Unresectable Stage IV Cutaneous Melanoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Dabrafenib and Trametinib for the Treatment of Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery

Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Unresectable Melanoma

United States
National Cancer Institute (NCI)
Fox Chase Cancer Center

Completed

Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma (Mel47)

Stage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma

United States
Vastra Gotaland Region
Miltenyi Biomedicine GmbH

Recruiting

Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases (HAITILS)

Metastatic Cutaneous Melanoma | Metastatic Uveal Melanoma

Sweden
Evaxion Biotech A/S
Novotech (Australia) Pty Limited

Terminated

Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1

Melanoma Stage IV | Melanoma Stage III

Australia
Piramal Enterprises Limited
Melanoma Research Foundation Breakthrough Consortium

Suspended

Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation

Advanced or Inoperable Malignant Melanoma With BRAF Mutation

United States
Power Life Sciences Inc.

Not yet recruiting

Investigating Participation Patterns Among Stage IV Melanoma Patients

Stage IV Melanoma

United States
Fudan University

Not yet recruiting

Envafolimab Combined With Recombinant Human Endostatin and First-line Chemotherapy Treat of Advanced Mucosal Melanoma

Advanced Mucosal Melanoma
Melanoma Institute Australia
Bristol-Myers Squibb

Recruiting

A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma (Neo ReNi II)

Stage II Melanoma

Australia
Washington University School of Medicine
Genentech, Inc.

Terminated

Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection

Stage II Melanoma

United States
Melanoma Institute Australia
Merck Sharp & Dohme LLC

Active, not recruiting

A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma (Neo PeLe)

Melanoma Stage III

Australia
Institut Curie

Completed

Study of Circulating Tumoral DNA in Metastatic Choroidal Melanoma

Choroidal Melanoma, Diffuse

France
Novo Nordisk A/S

Completed

Efficacy Study of IL-21 to Treat Metastatic Melanoma

Cancer | Malignant Melanoma

Australia
Bristol-Myers Squibb

Completed

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma (IMAGE)

Advanced Cutaneous Melanoma

Germany, Poland, Spain, Australia, France, Argentina, Ireland, Israel, Belgium, United States, Switzerland, United Kingdom, Greece, Austria, Canada
Mayo Clinic
Merck Sharp & Dohme LLC

Terminated

Immune Predictors of Response to Pembrolizumab Therapy in Stage IV Melanoma Patients

Stage IV Melanoma

United States
M.D. Anderson Cancer Center
Genta Incorporated

Completed

Phase II Study of Tesetaxel in Metastatic Melanoma

Cancer | Advanced Melanoma

United States
Hoffmann-La Roche

Withdrawn

A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma

Malignant Melanoma, Neoplasms
Italian Network for Tumor Biotherapy
Bristol-Myers Squibb

Completed

A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma (NIBIT-M1)

Metastatic Malignant Melanoma

Italy
NYU Langone Health

Completed

Inducing Systemic Immunity and Regressions in Metastatic Melanoma

Metastatic Malignant Melanoma
Krankenhaus Nordwest

Terminated

Trial of Single Agent Sunitinib for Patients With Chemo-refractory Metastatic Melanoma

Chemo-refractory Melanoma

Germany
National Cancer Institute (NCI)

Completed

Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma

High-Risk Melanoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Melanoma

Stage IV Melanoma

United States
MedImmune LLC

Completed

Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma

Melanoma | Malignant Metastatic Melanoma

United States
BioNTech SE
Regeneron Pharmaceuticals

Active, not recruiting

Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma

Unresectable Melanoma | Melanoma Stage IV | Melanoma Stage III

United States, Spain, Germany, Italy, Australia, United Kingdom, Poland
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma

Recurrent Melanoma | Stage IV Melanoma | Stage III Melanoma
Vical

Completed

Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma

Recurrent Melanoma | Stage IV Melanoma | Stage III Melanoma

United States
Vical

Completed

Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma

Recurrent Melanoma | Stage IV Melanoma | Stage III Melanoma

United States
University of Southern California
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

Recurrent Melanoma | Stage IV Melanoma | Mucosal Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage... and other conditions

United States
PrimeVax Immuno-Oncology Inc.
Walter Reed Army Institute of Research (WRAIR)

Not yet recruiting

Intratumoral Injection of Dengue Virus-1 #45AZ5 (PV-001-DV) in Patients With Melanoma

Advanced Melanoma
Chinese University of Hong Kong

Completed

Pembrolizumab in Advanced/Metastatic Acral Lentiginous Melanoma

Acral Lentiginous Melanoma

Hong Kong
Carman Giacomantonio
Nova Scotia Health Authority

Withdrawn

The Response to Intralesional IL-2 and/or BCG Treatment for Cutaneous Metastatic Melanoma

Cutaneous Metastatic Melanoma
Columbia University
Merck Sharp & Dohme LLC

Terminated

MRI and PET to Assess Pembrolizumab Response (MPAK)

Malignant Melanoma, Metastatic

United States
Wilson Miller

Active, not recruiting

Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma

Metastatic Malignant Melanoma

Canada
Burzynski Research Institute

Terminated

Antineoplaston Therapy in Treating Patients With Stage IV Melanoma

Stage IV Melanoma

United States
Lynn E. Spitler, MD
University of California, San Francisco

Completed

Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma (GIPI)

Malignant Melanoma, Metastatic

United States

Clinical Trials on Nasopharyngeal Melanoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations